| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue Engineering | 51 | 2020 | 695 | 4.950 |
Why?
|
| Stem Cells | 29 | 2018 | 321 | 3.830 |
Why?
|
| Tissue Scaffolds | 35 | 2020 | 431 | 3.630 |
Why?
|
| Cell Differentiation | 24 | 2020 | 461 | 3.090 |
Why?
|
| Bioengineering | 13 | 2017 | 77 | 3.020 |
Why?
|
| Extracellular Matrix | 27 | 2020 | 256 | 2.680 |
Why?
|
| Liver | 18 | 2020 | 492 | 2.390 |
Why?
|
| Endothelial Cells | 18 | 2016 | 193 | 2.310 |
Why?
|
| Organoids | 10 | 2020 | 99 | 2.270 |
Why?
|
| Neovascularization, Physiologic | 10 | 2016 | 114 | 2.230 |
Why?
|
| Amniotic Fluid | 11 | 2013 | 85 | 2.140 |
Why?
|
| Animals | 82 | 2020 | 8199 | 2.070 |
Why?
|
| Cell Proliferation | 26 | 2018 | 603 | 1.960 |
Why?
|
| Vascular Endothelial Growth Factor A | 18 | 2016 | 113 | 1.960 |
Why?
|
| Endothelium, Corneal | 5 | 2015 | 21 | 1.940 |
Why?
|
| Regenerative Medicine | 11 | 2018 | 217 | 1.830 |
Why?
|
| Amnion | 5 | 2019 | 36 | 1.720 |
Why?
|
| Stem Cell Transplantation | 11 | 2017 | 221 | 1.640 |
Why?
|
| Epithelial Cells | 6 | 2017 | 132 | 1.500 |
Why?
|
| Pancreas | 8 | 2020 | 107 | 1.460 |
Why?
|
| Trans-Activators | 4 | 2017 | 43 | 1.460 |
Why?
|
| Mice | 35 | 2020 | 2571 | 1.460 |
Why?
|
| Homeodomain Proteins | 4 | 2017 | 53 | 1.450 |
Why?
|
| Muscle, Skeletal | 9 | 2020 | 520 | 1.430 |
Why?
|
| Cells, Cultured | 34 | 2020 | 839 | 1.320 |
Why?
|
| Humans | 99 | 2020 | 32274 | 1.230 |
Why?
|
| Blood Vessel Prosthesis | 9 | 2014 | 82 | 1.220 |
Why?
|
| Colorectal Neoplasms | 4 | 2020 | 219 | 1.160 |
Why?
|
| Models, Biological | 4 | 2017 | 408 | 1.060 |
Why?
|
| Endothelium, Vascular | 10 | 2014 | 155 | 1.050 |
Why?
|
| Cell Culture Techniques | 15 | 2020 | 170 | 1.020 |
Why?
|
| Hydrogels | 8 | 2019 | 125 | 1.010 |
Why?
|
| Regeneration | 13 | 2016 | 178 | 0.990 |
Why?
|
| Biocompatible Materials | 12 | 2018 | 240 | 0.980 |
Why?
|
| Coculture Techniques | 5 | 2020 | 78 | 0.940 |
Why?
|
| Organ Transplantation | 6 | 2014 | 67 | 0.940 |
Why?
|
| Islets of Langerhans | 4 | 2020 | 73 | 0.930 |
Why?
|
| Collagen | 9 | 2020 | 229 | 0.840 |
Why?
|
| Kidney | 8 | 2017 | 521 | 0.780 |
Why?
|
| Bioreactors | 11 | 2017 | 58 | 0.780 |
Why?
|
| Myoblasts, Skeletal | 2 | 2016 | 21 | 0.770 |
Why?
|
| Insulin | 2 | 2016 | 359 | 0.760 |
Why?
|
| Insulin-Secreting Cells | 4 | 2020 | 49 | 0.730 |
Why?
|
| Tissue Array Analysis | 3 | 2017 | 34 | 0.720 |
Why?
|
| Neovascularization, Pathologic | 6 | 2005 | 75 | 0.690 |
Why?
|
| Cell Movement | 6 | 2013 | 167 | 0.680 |
Why?
|
| Rats | 17 | 2017 | 1895 | 0.680 |
Why?
|
| Bioprosthesis | 4 | 2014 | 60 | 0.670 |
Why?
|
| Neuropilin-1 | 8 | 2008 | 12 | 0.660 |
Why?
|
| Muscle Fibers, Skeletal | 5 | 2017 | 108 | 0.660 |
Why?
|
| Endothelial Growth Factors | 5 | 2002 | 12 | 0.650 |
Why?
|
| Blood Vessels | 4 | 2014 | 57 | 0.640 |
Why?
|
| Stromal Cells | 1 | 2020 | 66 | 0.620 |
Why?
|
| Cell Separation | 4 | 2015 | 89 | 0.620 |
Why?
|
| Wound Healing | 4 | 2019 | 185 | 0.610 |
Why?
|
| Compartment Syndromes | 3 | 2020 | 36 | 0.600 |
Why?
|
| Organogenesis | 3 | 2018 | 18 | 0.600 |
Why?
|
| Lymphokines | 4 | 2002 | 16 | 0.600 |
Why?
|
| Culture Media | 4 | 2016 | 48 | 0.600 |
Why?
|
| Fluorouracil | 3 | 2017 | 79 | 0.600 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2016 | 14 | 0.590 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2016 | 46 | 0.590 |
Why?
|
| Immunohistochemistry | 12 | 2017 | 543 | 0.560 |
Why?
|
| Fluorescent Dyes | 2 | 2018 | 52 | 0.560 |
Why?
|
| Muscle Development | 2 | 2018 | 52 | 0.550 |
Why?
|
| Corneal Transplantation | 2 | 2015 | 14 | 0.540 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2017 | 100 | 0.540 |
Why?
|
| Bile Ducts | 1 | 2018 | 19 | 0.540 |
Why?
|
| Skin | 4 | 2020 | 212 | 0.540 |
Why?
|
| Mesenchymal Stem Cells | 5 | 2017 | 165 | 0.530 |
Why?
|
| Mucous Membrane | 1 | 2017 | 27 | 0.530 |
Why?
|
| Rheology | 3 | 2016 | 35 | 0.530 |
Why?
|
| Activins | 1 | 2017 | 3 | 0.530 |
Why?
|
| Occupational Exposure | 2 | 2016 | 159 | 0.530 |
Why?
|
| Ethanol | 3 | 2015 | 195 | 0.530 |
Why?
|
| Niacinamide | 1 | 2017 | 8 | 0.530 |
Why?
|
| Mice, Nude | 8 | 2020 | 285 | 0.520 |
Why?
|
| Heparin | 2 | 2016 | 65 | 0.520 |
Why?
|
| Hepatocytes | 8 | 2018 | 80 | 0.520 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 164 | 0.510 |
Why?
|
| Liver Transplantation | 6 | 2014 | 185 | 0.500 |
Why?
|
| Myocytes, Cardiac | 3 | 2017 | 90 | 0.500 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 729 | 0.500 |
Why?
|
| Ferrets | 6 | 2018 | 20 | 0.490 |
Why?
|
| Cell Cycle | 1 | 2016 | 75 | 0.490 |
Why?
|
| Cell Transplantation | 2 | 2014 | 65 | 0.490 |
Why?
|
| Mouth Mucosa | 2 | 2016 | 30 | 0.490 |
Why?
|
| Cells, Immobilized | 1 | 2016 | 22 | 0.480 |
Why?
|
| Wounds and Injuries | 2 | 2016 | 242 | 0.480 |
Why?
|
| Swine | 9 | 2019 | 228 | 0.480 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 25 | 0.480 |
Why?
|
| Cytokines | 2 | 2017 | 237 | 0.470 |
Why?
|
| Cross-Linking Reagents | 2 | 2014 | 17 | 0.460 |
Why?
|
| Limbus Corneae | 1 | 2015 | 7 | 0.460 |
Why?
|
| Peptides | 1 | 2016 | 127 | 0.450 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 222 | 0.440 |
Why?
|
| Gelatin | 2 | 2016 | 29 | 0.440 |
Why?
|
| Apoptosis | 2 | 2016 | 375 | 0.440 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 478 | 0.430 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.420 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.420 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 1083 | 0.420 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.410 |
Why?
|
| Myocardium | 3 | 2020 | 184 | 0.410 |
Why?
|
| Cell Line | 5 | 2018 | 454 | 0.410 |
Why?
|
| Nicotine | 1 | 2016 | 164 | 0.410 |
Why?
|
| Bioartificial Organs | 3 | 2014 | 26 | 0.410 |
Why?
|
| Fetal Stem Cells | 2 | 2010 | 10 | 0.400 |
Why?
|
| Cell Survival | 10 | 2020 | 288 | 0.400 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.400 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2013 | 41 | 0.390 |
Why?
|
| Hep G2 Cells | 4 | 2016 | 24 | 0.380 |
Why?
|
| Elastic Modulus | 1 | 2012 | 29 | 0.380 |
Why?
|
| Muscles | 1 | 2012 | 69 | 0.370 |
Why?
|
| Phenotype | 3 | 2020 | 621 | 0.360 |
Why?
|
| Kidney Transplantation | 6 | 2014 | 490 | 0.360 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 50 | 0.350 |
Why?
|
| Osteogenesis | 3 | 2010 | 79 | 0.350 |
Why?
|
| General Surgery | 1 | 2012 | 84 | 0.340 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.340 |
Why?
|
| Aging | 3 | 2017 | 942 | 0.330 |
Why?
|
| Hyaluronic Acid | 4 | 2018 | 51 | 0.320 |
Why?
|
| Corneal Stroma | 1 | 2010 | 5 | 0.320 |
Why?
|
| Neoplasms | 2 | 2016 | 754 | 0.320 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 6 | 2015 | 22 | 0.310 |
Why?
|
| Organ Culture Techniques | 2 | 2013 | 44 | 0.310 |
Why?
|
| Tissue Donors | 2 | 2010 | 186 | 0.310 |
Why?
|
| Calcinosis | 1 | 2010 | 143 | 0.300 |
Why?
|
| Female | 23 | 2020 | 19942 | 0.290 |
Why?
|
| Cell Fractionation | 1 | 2009 | 8 | 0.290 |
Why?
|
| Cell-Free System | 1 | 2009 | 16 | 0.290 |
Why?
|
| Ferric Compounds | 1 | 2008 | 15 | 0.290 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2007 | 38 | 0.290 |
Why?
|
| Cell Lineage | 3 | 2018 | 65 | 0.280 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2005 | 20 | 0.280 |
Why?
|
| Male | 22 | 2020 | 19437 | 0.280 |
Why?
|
| Perfusion | 4 | 2020 | 75 | 0.280 |
Why?
|
| Materials Testing | 6 | 2015 | 89 | 0.280 |
Why?
|
| Nerve Tissue Proteins | 3 | 2013 | 124 | 0.280 |
Why?
|
| Endostatins | 2 | 2007 | 3 | 0.270 |
Why?
|
| Sus scrofa | 5 | 2015 | 47 | 0.270 |
Why?
|
| Rats, Inbred Lew | 6 | 2020 | 123 | 0.260 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 114 | 0.260 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 56 | 0.260 |
Why?
|
| Rabbits | 4 | 2017 | 219 | 0.260 |
Why?
|
| Central Nervous System Depressants | 1 | 2007 | 63 | 0.260 |
Why?
|
| Carotid Arteries | 3 | 2012 | 109 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 106 | 0.250 |
Why?
|
| Angiogenesis Modulating Agents | 1 | 2006 | 1 | 0.250 |
Why?
|
| Growth Substances | 1 | 2006 | 9 | 0.250 |
Why?
|
| Liver Regeneration | 3 | 2017 | 23 | 0.250 |
Why?
|
| Urethra | 3 | 2012 | 125 | 0.240 |
Why?
|
| Microscopy, Fluorescence | 4 | 2014 | 93 | 0.240 |
Why?
|
| Heart | 4 | 2017 | 177 | 0.240 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 465 | 0.240 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 70 | 0.230 |
Why?
|
| Urinary Bladder | 4 | 2012 | 320 | 0.230 |
Why?
|
| Optical Phenomena | 2 | 2015 | 6 | 0.230 |
Why?
|
| Neuroblastoma | 1 | 2005 | 32 | 0.230 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 595 | 0.230 |
Why?
|
| Gold | 1 | 2005 | 19 | 0.230 |
Why?
|
| Collagen Type IV | 2 | 2016 | 10 | 0.220 |
Why?
|
| Pressure | 3 | 2013 | 69 | 0.210 |
Why?
|
| Blotting, Western | 4 | 2016 | 299 | 0.210 |
Why?
|
| Hemodynamics | 2 | 2015 | 164 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 1223 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2016 | 897 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 246 | 0.190 |
Why?
|
| Stress, Mechanical | 4 | 2017 | 96 | 0.190 |
Why?
|
| Fibronectins | 2 | 2013 | 39 | 0.190 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 26 | 0.190 |
Why?
|
| Fiber Optic Technology | 2 | 2013 | 13 | 0.190 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2012 | 61 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2002 | 13 | 0.190 |
Why?
|
| Gene Expression | 3 | 2013 | 345 | 0.190 |
Why?
|
| Receptors, Mitogen | 1 | 2002 | 2 | 0.180 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 2 | 0.180 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 18 | 0.180 |
Why?
|
| Immune Tolerance | 3 | 2014 | 66 | 0.180 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 146 | 0.180 |
Why?
|
| Biopsy | 2 | 2020 | 252 | 0.170 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 78 | 0.170 |
Why?
|
| Models, Animal | 4 | 2012 | 188 | 0.170 |
Why?
|
| Gastrointestinal Tract | 2 | 2012 | 40 | 0.170 |
Why?
|
| Phosphorylation | 5 | 2009 | 250 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 6 | 2010 | 24 | 0.170 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2020 | 29 | 0.170 |
Why?
|
| Intestines | 2 | 2012 | 63 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 2 | 2014 | 196 | 0.170 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 257 | 0.170 |
Why?
|
| Mice, SCID | 3 | 2008 | 73 | 0.170 |
Why?
|
| Time Factors | 6 | 2016 | 2204 | 0.160 |
Why?
|
| Proteome | 1 | 2020 | 41 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2002 | 131 | 0.160 |
Why?
|
| Flow Cytometry | 3 | 2011 | 183 | 0.160 |
Why?
|
| Myoblasts | 2 | 2012 | 41 | 0.160 |
Why?
|
| Acetylcysteine | 1 | 2020 | 9 | 0.160 |
Why?
|
| Transfection | 4 | 2005 | 204 | 0.160 |
Why?
|
| HCT116 Cells | 2 | 2017 | 10 | 0.150 |
Why?
|
| Urinary Incontinence, Stress | 2 | 2012 | 75 | 0.150 |
Why?
|
| Cystitis | 2 | 2010 | 8 | 0.150 |
Why?
|
| Immunosuppression | 4 | 2013 | 118 | 0.150 |
Why?
|
| Adult | 10 | 2016 | 9256 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 38 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2017 | 68 | 0.150 |
Why?
|
| Calcium | 3 | 2017 | 339 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 534 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2017 | 727 | 0.140 |
Why?
|
| Cell Adhesion | 4 | 2013 | 100 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 150 | 0.140 |
Why?
|
| Collagen Type I | 1 | 2018 | 44 | 0.140 |
Why?
|
| Adenoviridae | 2 | 2012 | 68 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 4 | 2016 | 164 | 0.140 |
Why?
|
| Myogenic Regulatory Factor 5 | 1 | 2018 | 7 | 0.140 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2018 | 4 | 0.140 |
Why?
|
| Wnt Proteins | 1 | 2018 | 17 | 0.140 |
Why?
|
| Genes, Immediate-Early | 1 | 2017 | 3 | 0.140 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2011 | 90 | 0.130 |
Why?
|
| Fetal Blood | 1 | 2018 | 34 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 717 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 89 | 0.130 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 27 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 792 | 0.130 |
Why?
|
| Biosensing Techniques | 1 | 2017 | 24 | 0.130 |
Why?
|
| Lung | 2 | 2017 | 263 | 0.130 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 42 | 0.130 |
Why?
|
| Cattle | 4 | 2011 | 116 | 0.130 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2017 | 6 | 0.130 |
Why?
|
| Gluconates | 1 | 2016 | 4 | 0.130 |
Why?
|
| Ouabain | 1 | 2016 | 6 | 0.130 |
Why?
|
| PAX7 Transcription Factor | 1 | 2016 | 10 | 0.130 |
Why?
|
| Splenomegaly | 1 | 2016 | 6 | 0.130 |
Why?
|
| Mice, Inbred ICR | 3 | 2016 | 11 | 0.130 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 7 | 0.130 |
Why?
|
| Cosmic Radiation | 1 | 2016 | 10 | 0.130 |
Why?
|
| Potassium | 1 | 2016 | 40 | 0.130 |
Why?
|
| Membrane Potentials | 1 | 2016 | 76 | 0.120 |
Why?
|
| Dogs | 2 | 2014 | 126 | 0.120 |
Why?
|
| Liver, Artificial | 1 | 2016 | 5 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 57 | 0.120 |
Why?
|
| Developmental Biology | 2 | 2018 | 6 | 0.120 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 17 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 39 | 0.120 |
Why?
|
| Polyesters | 3 | 2016 | 76 | 0.120 |
Why?
|
| Dental Pulp | 1 | 2016 | 1 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2016 | 85 | 0.120 |
Why?
|
| Cadherins | 1 | 2016 | 28 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 70 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2016 | 854 | 0.120 |
Why?
|
| Toxicity Tests | 1 | 2015 | 12 | 0.120 |
Why?
|
| Optical Fibers | 1 | 2015 | 4 | 0.120 |
Why?
|
| Transplantation, Heterologous | 2 | 2008 | 109 | 0.110 |
Why?
|
| Umbilical Veins | 3 | 2005 | 13 | 0.110 |
Why?
|
| Surface Properties | 2 | 2012 | 37 | 0.110 |
Why?
|
| Microvessels | 1 | 2015 | 30 | 0.110 |
Why?
|
| Kidney Glomerulus | 1 | 2015 | 28 | 0.110 |
Why?
|
| Neoplasm Transplantation | 2 | 2005 | 73 | 0.110 |
Why?
|
| Middle Aged | 6 | 2016 | 11848 | 0.110 |
Why?
|
| Nitric Oxide | 1 | 2016 | 121 | 0.110 |
Why?
|
| Jugular Veins | 2 | 2012 | 24 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2014 | 239 | 0.110 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2012 | 46 | 0.110 |
Why?
|
| Transplants | 2 | 2014 | 22 | 0.110 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2013 | 15 | 0.110 |
Why?
|
| Desmin | 2 | 2011 | 12 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 312 | 0.110 |
Why?
|
| Mullerian Ducts | 1 | 2014 | 3 | 0.110 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 9 | 0.100 |
Why?
|
| Graft Rejection | 2 | 2014 | 236 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2014 | 553 | 0.100 |
Why?
|
| Ossification, Heterotopic | 1 | 2014 | 21 | 0.100 |
Why?
|
| Equipment Design | 4 | 2017 | 178 | 0.100 |
Why?
|
| Transplantation Immunology | 2 | 2010 | 30 | 0.100 |
Why?
|
| Aged | 4 | 2016 | 10260 | 0.100 |
Why?
|
| Vagina | 1 | 2014 | 61 | 0.100 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2020 | 102 | 0.100 |
Why?
|
| Chickens | 1 | 2013 | 36 | 0.100 |
Why?
|
| Detergents | 1 | 2013 | 17 | 0.100 |
Why?
|
| Antigens | 1 | 2013 | 34 | 0.100 |
Why?
|
| Collagenases | 1 | 2013 | 9 | 0.100 |
Why?
|
| Drug Discovery | 3 | 2018 | 38 | 0.100 |
Why?
|
| Age Factors | 2 | 2014 | 1179 | 0.100 |
Why?
|
| Maf Transcription Factors, Large | 1 | 2013 | 2 | 0.100 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 264 | 0.100 |
Why?
|
| Platelet Activating Factor | 2 | 2004 | 15 | 0.100 |
Why?
|
| Biomedical Engineering | 2 | 2013 | 28 | 0.100 |
Why?
|
| Laminin | 1 | 2013 | 13 | 0.100 |
Why?
|
| Integrins | 1 | 2013 | 17 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 38 | 0.100 |
Why?
|
| Graft Survival | 2 | 2011 | 293 | 0.100 |
Why?
|
| Culture Media, Serum-Free | 1 | 2012 | 15 | 0.100 |
Why?
|
| Implants, Experimental | 1 | 2012 | 13 | 0.090 |
Why?
|
| C-Peptide | 1 | 2012 | 31 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 1 | 2013 | 47 | 0.090 |
Why?
|
| Fibrin | 1 | 2012 | 33 | 0.090 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 50 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 40 | 0.090 |
Why?
|
| Larynx | 1 | 2012 | 17 | 0.090 |
Why?
|
| Chondroitin Sulfates | 1 | 2012 | 23 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 267 | 0.090 |
Why?
|
| Skin, Artificial | 1 | 2012 | 34 | 0.090 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 34 | 0.090 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.090 |
Why?
|
| Muscle, Striated | 1 | 2012 | 4 | 0.090 |
Why?
|
| Pancreatic Diseases | 1 | 2012 | 21 | 0.090 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 17 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 73 | 0.090 |
Why?
|
| Myositis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Liver Failure | 1 | 2012 | 21 | 0.090 |
Why?
|
| Solubility | 2 | 2020 | 39 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2013 | 456 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2012 | 43 | 0.090 |
Why?
|
| Transplantation Tolerance | 1 | 2011 | 14 | 0.090 |
Why?
|
| Edema | 1 | 2011 | 29 | 0.090 |
Why?
|
| Ligation | 1 | 2011 | 64 | 0.090 |
Why?
|
| Urinary Incontinence | 1 | 2012 | 68 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2011 | 74 | 0.080 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2011 | 17 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 655 | 0.080 |
Why?
|
| Azacitidine | 1 | 2011 | 27 | 0.080 |
Why?
|
| Cell Communication | 1 | 2011 | 37 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2011 | 135 | 0.080 |
Why?
|
| Macaca fascicularis | 1 | 2013 | 542 | 0.080 |
Why?
|
| Urethral Stricture | 1 | 2011 | 31 | 0.080 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2010 | 13 | 0.080 |
Why?
|
| Pregnancy | 2 | 2012 | 961 | 0.080 |
Why?
|
| Chondrocytes | 1 | 2011 | 70 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 55 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2011 | 136 | 0.080 |
Why?
|
| Cell Division | 4 | 2005 | 92 | 0.080 |
Why?
|
| Osteopontin | 1 | 2010 | 4 | 0.080 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2010 | 37 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 40 | 0.080 |
Why?
|
| Cell Count | 1 | 2010 | 51 | 0.080 |
Why?
|
| Trachea | 1 | 2010 | 53 | 0.080 |
Why?
|
| Nanotechnology | 2 | 2012 | 18 | 0.080 |
Why?
|
| Rats, Nude | 1 | 2010 | 48 | 0.080 |
Why?
|
| Mechanical Phenomena | 1 | 2010 | 29 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2012 | 276 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2009 | 15 | 0.080 |
Why?
|
| Nanostructures | 1 | 2009 | 20 | 0.080 |
Why?
|
| Osteoblasts | 1 | 2009 | 43 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 390 | 0.080 |
Why?
|
| Inflammation | 1 | 2012 | 506 | 0.070 |
Why?
|
| Guided Tissue Regeneration | 2 | 2008 | 39 | 0.070 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2011 | 191 | 0.070 |
Why?
|
| NIH 3T3 Cells | 2 | 2007 | 41 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2009 | 7 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 314 | 0.070 |
Why?
|
| Pancreas Transplantation | 1 | 2010 | 245 | 0.070 |
Why?
|
| Keratinocytes | 2 | 2020 | 30 | 0.070 |
Why?
|
| Parthenogenesis | 1 | 2008 | 7 | 0.070 |
Why?
|
| DNA Primers | 3 | 2005 | 84 | 0.070 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 16 | 0.070 |
Why?
|
| Vascular Patency | 3 | 2014 | 66 | 0.070 |
Why?
|
| Neuropilins | 1 | 2008 | 1 | 0.070 |
Why?
|
| Adolescent | 6 | 2014 | 3517 | 0.070 |
Why?
|
| Genetic Engineering | 1 | 2008 | 22 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2020 | 119 | 0.070 |
Why?
|
| Base Sequence | 3 | 2005 | 252 | 0.070 |
Why?
|
| Oocytes | 1 | 2008 | 45 | 0.070 |
Why?
|
| Penis | 1 | 2008 | 45 | 0.070 |
Why?
|
| Nerve Regeneration | 1 | 2008 | 50 | 0.070 |
Why?
|
| Immunochemistry | 1 | 2007 | 8 | 0.070 |
Why?
|
| Urine | 1 | 2008 | 69 | 0.070 |
Why?
|
| Blood Cells | 1 | 2007 | 9 | 0.070 |
Why?
|
| Thrombospondins | 1 | 2007 | 6 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2007 | 29 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 47 | 0.070 |
Why?
|
| Spheroids, Cellular | 2 | 2020 | 36 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2008 | 69 | 0.070 |
Why?
|
| Microtubules | 1 | 2007 | 18 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2008 | 85 | 0.070 |
Why?
|
| Chondrogenesis | 1 | 2007 | 19 | 0.070 |
Why?
|
| Pulsatile Flow | 3 | 2012 | 19 | 0.060 |
Why?
|
| Prostate | 1 | 2007 | 88 | 0.060 |
Why?
|
| Pluripotent Stem Cells | 1 | 2007 | 18 | 0.060 |
Why?
|
| Transforming Growth Factors | 1 | 2006 | 1 | 0.060 |
Why?
|
| Prosthesis Design | 3 | 2012 | 106 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2006 | 16 | 0.060 |
Why?
|
| Sheep | 3 | 2012 | 194 | 0.060 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2006 | 13 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2007 | 113 | 0.060 |
Why?
|
| Macaca mulatta | 1 | 2007 | 340 | 0.060 |
Why?
|
| Adipogenesis | 1 | 2006 | 30 | 0.060 |
Why?
|
| Hemangioma | 1 | 2006 | 23 | 0.060 |
Why?
|
| Urinary Bladder Diseases | 1 | 2006 | 44 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 120 | 0.060 |
Why?
|
| Polyethylene Glycols | 2 | 2016 | 63 | 0.060 |
Why?
|
| Glycolates | 1 | 2005 | 7 | 0.060 |
Why?
|
| Elastin | 1 | 2005 | 16 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2005 | 36 | 0.060 |
Why?
|
| Genetic Enhancement | 1 | 2005 | 4 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 29 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2002 | 60 | 0.060 |
Why?
|
| Protein Engineering | 1 | 2005 | 19 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2007 | 200 | 0.060 |
Why?
|
| Intracellular Space | 1 | 2005 | 17 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 36 | 0.060 |
Why?
|
| Heart Failure | 1 | 2012 | 728 | 0.060 |
Why?
|
| Particle Size | 1 | 2005 | 48 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 2 | 2017 | 70 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 33 | 0.060 |
Why?
|
| Quinazolines | 1 | 2005 | 35 | 0.060 |
Why?
|
| Child | 5 | 2011 | 2434 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2020 | 471 | 0.050 |
Why?
|
| Protein Binding | 2 | 2002 | 244 | 0.050 |
Why?
|
| Piperidines | 1 | 2005 | 137 | 0.050 |
Why?
|
| Fibrosis | 2 | 2017 | 126 | 0.050 |
Why?
|
| P-Selectin | 1 | 2004 | 10 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 95 | 0.050 |
Why?
|
| U937 Cells | 1 | 2002 | 6 | 0.050 |
Why?
|
| Leukemia, Experimental | 1 | 2002 | 3 | 0.050 |
Why?
|
| Regional Blood Flow | 2 | 2013 | 85 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 18 | 0.050 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2002 | 24 | 0.050 |
Why?
|
| Polyglycolic Acid | 3 | 2011 | 32 | 0.050 |
Why?
|
| Histocompatibility | 1 | 2002 | 7 | 0.050 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2002 | 9 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2002 | 78 | 0.050 |
Why?
|
| Optics and Photonics | 2 | 2012 | 7 | 0.050 |
Why?
|
| Cloning, Organism | 1 | 2002 | 12 | 0.050 |
Why?
|
| Clone Cells | 3 | 2007 | 35 | 0.050 |
Why?
|
| Microcirculation | 2 | 2012 | 66 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 20 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 18 | 0.050 |
Why?
|
| Affinity Labels | 1 | 2002 | 2 | 0.050 |
Why?
|
| Porosity | 2 | 2012 | 39 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2002 | 108 | 0.050 |
Why?
|
| Acute Disease | 1 | 2002 | 253 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2002 | 43 | 0.040 |
Why?
|
| Tyrosine | 1 | 2002 | 24 | 0.040 |
Why?
|
| Ischemia | 1 | 2002 | 115 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2002 | 60 | 0.040 |
Why?
|
| Kinetics | 1 | 2002 | 250 | 0.040 |
Why?
|
| Homeostasis | 1 | 2002 | 130 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2002 | 204 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2002 | 499 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2014 | 3416 | 0.040 |
Why?
|
| Disease Progression | 1 | 2002 | 591 | 0.040 |
Why?
|
| Astemizole | 1 | 2020 | 5 | 0.040 |
Why?
|
| Mitomycin | 1 | 2020 | 50 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2020 | 14 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2012 | 308 | 0.040 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 84 | 0.040 |
Why?
|
| Cystoscopy | 2 | 2011 | 27 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2020 | 154 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 248 | 0.030 |
Why?
|
| Electric Stimulation | 2 | 2008 | 135 | 0.030 |
Why?
|
| Transplantation | 1 | 2018 | 12 | 0.030 |
Why?
|
| Urothelium | 2 | 2008 | 64 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 2017 | 28 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 46 | 0.030 |
Why?
|
| Heart Rate | 1 | 2020 | 362 | 0.030 |
Why?
|
| Microfluidics | 1 | 2017 | 18 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2017 | 57 | 0.030 |
Why?
|
| Administration, Intravesical | 2 | 2010 | 28 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 221 | 0.030 |
Why?
|
| Body Burden | 1 | 2016 | 5 | 0.030 |
Why?
|
| Astronauts | 1 | 2016 | 10 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 443 | 0.030 |
Why?
|
| Colon | 1 | 2017 | 72 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 99 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 101 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2016 | 43 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 91 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2007 | 24 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 130 | 0.030 |
Why?
|
| Stage-Specific Embryonic Antigens | 1 | 2016 | 1 | 0.030 |
Why?
|
| Tubulin | 1 | 2016 | 11 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2016 | 27 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2016 | 44 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 323 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 14 | 0.030 |
Why?
|
| Corrosion Casting | 1 | 2015 | 10 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2015 | 13 | 0.030 |
Why?
|
| Lasers | 1 | 2015 | 22 | 0.030 |
Why?
|
| Solutions | 1 | 2015 | 40 | 0.030 |
Why?
|
| Urea | 1 | 2015 | 38 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 42 | 0.030 |
Why?
|
| Transplantation, Autologous | 2 | 2008 | 100 | 0.030 |
Why?
|
| Feedback | 1 | 2015 | 41 | 0.030 |
Why?
|
| Glycosaminoglycans | 2 | 2007 | 23 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2014 | 37 | 0.030 |
Why?
|
| Metaplasia | 1 | 2014 | 19 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 144 | 0.030 |
Why?
|
| Quartz | 1 | 2013 | 1 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2013 | 34 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2012 | 5 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 18 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2012 | 17 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 22 | 0.020 |
Why?
|
| Viscosity | 1 | 2012 | 25 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 44 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2012 | 34 | 0.020 |
Why?
|
| Elasticity | 1 | 2012 | 41 | 0.020 |
Why?
|
| Punctures | 1 | 2012 | 32 | 0.020 |
Why?
|
| Needles | 1 | 2012 | 29 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 45 | 0.020 |
Why?
|
| Infant | 2 | 2006 | 1010 | 0.020 |
Why?
|
| Silicon Dioxide | 1 | 2012 | 8 | 0.020 |
Why?
|
| Photons | 1 | 2012 | 8 | 0.020 |
Why?
|
| Electrons | 1 | 2012 | 12 | 0.020 |
Why?
|
| Injections | 1 | 2012 | 72 | 0.020 |
Why?
|
| Light | 1 | 2012 | 35 | 0.020 |
Why?
|
| Microspheres | 1 | 2012 | 45 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 50 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 74 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 70 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2006 | 1233 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2012 | 85 | 0.020 |
Why?
|
| Mexico | 1 | 2011 | 47 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 187 | 0.020 |
Why?
|
| Actins | 1 | 2011 | 54 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2011 | 50 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2011 | 42 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2010 | 16 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 48 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2011 | 45 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 158 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 62 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 5 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 26 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2010 | 34 | 0.020 |
Why?
|
| Crystallization | 1 | 2009 | 18 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1840 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2009 | 5 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 37 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 43 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 965 | 0.020 |
Why?
|
| MyoD Protein | 1 | 2008 | 10 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 68 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2008 | 42 | 0.020 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2008 | 22 | 0.020 |
Why?
|
| Femoral Nerve | 1 | 2008 | 8 | 0.020 |
Why?
|
| Neuropilin-2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2008 | 10 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 10 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2012 | 861 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 238 | 0.020 |
Why?
|
| Integrin alpha6 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2007 | 16 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 23 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 964 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2007 | 8 | 0.020 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 907 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 21 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 74 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 2648 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cartilage | 1 | 2007 | 33 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 63 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 556 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 292 | 0.020 |
Why?
|
| Meningomyelocele | 1 | 2006 | 9 | 0.020 |
Why?
|
| Granuloma, Pyogenic | 1 | 2006 | 5 | 0.010 |
Why?
|
| X Chromosome Inactivation | 1 | 2006 | 7 | 0.010 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2006 | 9 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2006 | 95 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2240 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 39 | 0.010 |
Why?
|
| Shear Strength | 1 | 2005 | 9 | 0.010 |
Why?
|
| Tensile Strength | 1 | 2005 | 60 | 0.010 |
Why?
|
| Circumcision, Male | 1 | 2005 | 3 | 0.010 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2005 | 3 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2005 | 56 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 55 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2006 | 96 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2005 | 124 | 0.010 |
Why?
|
| Adipocytes | 1 | 2005 | 69 | 0.010 |
Why?
|
| Neurons | 1 | 2008 | 486 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 80 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 666 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 220 | 0.010 |
Why?
|
| Neutrophils | 1 | 2004 | 120 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2008 | 823 | 0.010 |
Why?
|
| Hydrochloric Acid | 1 | 2002 | 4 | 0.010 |
Why?
|
| Lac Operon | 1 | 2002 | 5 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2002 | 11 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2002 | 111 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2002 | 3 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 88 | 0.010 |
Why?
|